Cancers,
Journal Year:
2022,
Volume and Issue:
14(13), P. 3145 - 3145
Published: June 27, 2022
This
review
aims
to
summarize
the
implications
of
major
isoforms
tumor
suppressor
protein
p53
in
aggressive
cancer
development.
The
current
knowledge
isoforms,
their
involvement
cell-signaling
pathways,
and
interactions
with
other
cellular
proteins
or
factors
suggests
existence
an
intricate
molecular
network
that
regulates
oncogenic
function.
Moreover,
existing
literature
about
various
cancers
leads
proposition
therapeutic
solutions
by
altering
levels
isoforms.
thus
summarizes
how
Δ40p53α/β/γ,
Δ133p53α/β/γ,
Δ160p53α/β/γ
might
have
clinical
relevance
diagnosis
effective
treatments
cancer.
Seminars in Cancer Biology,
Journal Year:
2022,
Volume and Issue:
86, P. 1086 - 1104
Published: Feb. 23, 2022
Recent
mounting
evidence
has
revealed
extensive
genetic
heterogeneity
within
tumors
that
drive
phenotypic
variation
affecting
key
cancer
pathways,
making
treatment
extremely
challenging.
Diverse
types
display
resistance
to
and
show
patterns
of
relapse
following
therapy.
Therefore,
efforts
are
required
address
tumor
by
developing
a
broad-spectrum
therapeutic
approach
combines
targeted
therapies.
Inflammation
been
progressively
documented
as
vital
factor
in
advancement
consequences
epigenetic
variations
support
instigation,
encouraging
all
the
tumorigenesis
phases.
Increased
DNA
damage,
disrupted
repair
mechanisms,
cellular
proliferation,
apoptosis,
angiogenesis,
its
incursion
few
pro-cancerous
outcomes
chronic
inflammation.
A
clear
understanding
molecular
signaling
mechanisms
tumor-endorsing
inflammation
is
necessary
for
further
expansion
anti-cancer
therapeutics
targeting
crosstalk
between
development
inflammatory
processes.
Multiple
such
NF-κB
pathway,
JAK-STAT
MAPK
signaling,
PI3K/AKT/mTOR
Wnt
cascade,
TGF-β/Smad
have
found
regulate
inflammation,
which
can
be
modulated
using
various
factors
small
molecule
inhibitors,
phytochemicals,
recombinant
cytokines,
nanoparticles
(NPs)
conjugation
phytochemicals
treat
cancer.
Researchers
identified
multiple
targets
specifically
alter
therapy
restrict
malignant
progression
improve
efficacy
siRNA-and
shRNA-loaded
NPs
observed
downregulate
STAT3
pathways
employed
studies
target
malignancies.
This
review
highlights
involved
interaction
progression,
along
with
novel
approaches
nanotechnology-based
drug
delivery
systems
currently
used
combat
Stem Cell Reviews and Reports,
Journal Year:
2022,
Volume and Issue:
18(7), P. 2209 - 2233
Published: July 25, 2022
The
physiological
state
of
the
tumor
microenvironment
(TME)
plays
a
central
role
in
cancer
development
due
to
multiple
universal
features
that
transcend
heterogeneity
and
niche
specifications,
like
promoting
progression
metastasis.
As
result
their
preponderant
involvement
growth
maintenance
through
several
microsystemic
alterations,
including
hypoxia,
oxidative
stress,
acidosis,
TMEs
make
for
ideal
targets
both
diagnostic
therapeutic
ventures.
Correspondingly,
methodologies
target
have
been
investigated
this
past
decade
as
stratagems
significant
potential
genre
focused
treatment.
Within
targeted
oncotherapy,
nanomedical
derivates-nanocarriers
(NCs)
especially-have
emerged
present
notable
prospects
enhancing
targeting
specificity.
Yet,
one
major
issue
application
NCs
microenvironmental
directed
therapy
is
are
too
broad
spectrum
possibilities
these
carriers
be
effectively
employed.
However,
stem
cells
(CSCs)
might
portend
solution
above
conundrum:
aside
from
being
quite
heavily
invested
tumorigenesis
resistance,
CSCs
also
show
self-renewal
fluid
clonogenic
properties
often
define
specific
TME
niches.
Further
scrutiny
relationship
between
points
towards
mechanisms
underly
tumoral
characteristics
metastasis,
malignancy,
even
resistance.
This
review
summarizes
recent
advances
NC-enabled
more
holistic
strikes
against
discusses
current
challenges
hinder
clinical
strategies
well
avenues
can
further
CSC-targeting
initiatives.
Central
regulation
cellular
components
within
TME.
Cancers,
Journal Year:
2022,
Volume and Issue:
14(13), P. 3145 - 3145
Published: June 27, 2022
This
review
aims
to
summarize
the
implications
of
major
isoforms
tumor
suppressor
protein
p53
in
aggressive
cancer
development.
The
current
knowledge
isoforms,
their
involvement
cell-signaling
pathways,
and
interactions
with
other
cellular
proteins
or
factors
suggests
existence
an
intricate
molecular
network
that
regulates
oncogenic
function.
Moreover,
existing
literature
about
various
cancers
leads
proposition
therapeutic
solutions
by
altering
levels
isoforms.
thus
summarizes
how
Δ40p53α/β/γ,
Δ133p53α/β/γ,
Δ160p53α/β/γ
might
have
clinical
relevance
diagnosis
effective
treatments
cancer.
